Research programme: protein kinase C alpha inhibitors - Clinical Value Corporation

Drug Profile

Research programme: protein kinase C alpha inhibitors - Clinical Value Corporation

Alternative Names: GAP-107B8; PhGα1; TIM-10

Latest Information Update: 28 Feb 2014

Price : $50

At a glance

  • Originator PharmaGap
  • Developer PharmaGap; Queens University
  • Class Antineoplastics; Peptides
  • Mechanism of Action Protein kinase C-alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Hypertension; Ovarian cancer; Solid tumours

Most Recent Events

  • 04 Feb 2013 Discontinued - Preclinical for Solid tumours in Canada (Intraperitoneal)
  • 04 Feb 2013 Discontinued - Preclinical for Ovarian cancer in Canada (Intraperitoneal)
  • 04 Feb 2013 Discontinued - Preclinical for Bladder cancer in Canada (Intravesicular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top